Clinical Trial Search

Primary: Presence/Absence of Reflux Esophagitis Relapse — 0; 1; 7; 18 Participants

Primary: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure — 0.23; 0.43; 0.45 proportion of…

Primary: Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs…

Primary: Change From Baseline in pVO2 at Week 24 — 1.76; 0.02 mL/kg/min — p=<0.0001

Primary: Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10 — -85.7; -89.5; 38.8 Percent change — p=0.0022

Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 48.68; 64.5; 11.49 percentage of participants — p=<0.0001

Primary: Percentage Change in Body Weight — -14.4; -2.5 Percentage change in body weight — p=<0.0001

Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 57.38; 70.59; 7.85 percentage of participants — p=<0.0001

Primary: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 — -58.2; 2.6 Percent Change — p=<0.001

Primary: Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) — 41.25; 21.00 Differentially expressed genes

Primary: Change in WOMAC Pain (0-20 Scale) — -0.14; -0.65 units on a scale

Primary: Risky Driving Events — 101.3; 106.2; 77.7 Average number of events per 1000 miles

Primary: Self-reported Pain After Laser Treatment — 4.5; 5.0 score on a scale — p=0.102

Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants

Primary: Percentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16 — 3.0; 94.0 percentage of participants — p=<0.001